(RTTNews) - AstraZeneca reported that Soliris has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis in paediatric patients who are anti-acetylcholine ...
FILE PHOTO: An Amgen sign is seen at the company's headquarters in Thousand Oaks (Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca ...
An AstraZeneca drug acquired in a $930 million deal has received FDA approval as a treatment for a rare blood disorder. In this disease, paroxysmal nocturnal hemoglobinuria (PNH), a part of the immune ...
Teva Pharmaceutical (NYSE:TEVA) and South Korean generic drugmaker Samsung Bioepis announced Monday the U.S. commercial availability of Epysqli, a biosimilar drug targeting AstraZeneca’s (NASDAQ:AZN) ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The expanded application makes this the first available ...
New, long-term data for VOYDEYA™ as add-on to ULTOMIRIS® or SOLIRIS® will show low rate of breakthrough hemolysis events and sustained improvements in quality-of-life measures in PNH with ...
The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated ...
SOLIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. SOLIRIS increases your chance of getting serious and life-threatening ...
(RTTNews) - AstraZeneca (AZN, AZN.L) said that positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback